Implications of Phase 3 Trial Results Assessing Efficacy, Safety of Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19

Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.

During the discussion, Kosiborod explained the implications of the trial results on the treatment opportunities available for this patient population.